Journal of Posthumanism

2025
Volume: 5, No: 1, pp. 1560–1580
ISSN: 2634-3576 (Print) | ISSN 2634-3584 (Online)
posthumanism.co.uk

DOI: https://doi.org/10.63332/joph.v5i1.1993

AI-Driven Precision Medicine Leveraging Machine Learning and Big Data Analytics for Genomics-Based Drug Discovery

Mia Md Tofayel Gonee Manik[1], Sraboni Clara Mohonta[2], Farhana Karim[3], Md Alamgir Miah[4], Md Shafiqul Islam[5], Md Asikur Rahman Chy[6], Muhammad Adnan[7], Abu Saleh Muhammad Saimon[8]

Abstract

The clinical use of artificial intelligence for precision medicine delivers transformative results in drug discovery through its combination of big data analytics and machine learning with genomic research. The traditional methods used in the drug discovery process are expensive to implement and take lengthy durations while failing to deliver customized therapy for patients. The advent of artificial intelligence now conducts fast genomic database analysis to find new drug aims and develop targeted medicine for individual patients. The application of ML algorithms enables researchers to make disease progression forecasts as well as identify drug effectiveness and potential adverse effects leading to improved outcomes for genomic drug discovery patients. The research discusses how deep learning and reinforcement learning models are applied to work with big genomic and biomedical information datasets. Data storage through cloud computing platforms together with high-performance computing systems allows precision medicine to scale and become more efficient. AI computational biology combined with clinical information enhances pharma research by optimally structuring drug reuse analysis and promoting new drug development processes. The use of artificial intelligence leads genomics-based drug discovery to a new direction through high efficiency and cost reduction and individual patient therapy delivery. Precision medicine based on AI and bioinformatics advancements push forward personal healthcare into the future despite ongoing obstacles such as data security problems and interpretation challenges and regulatory limitations.

Keywords: *AI-Driven Precision Medicine, Machine Learning, Big Data Analytics, Genomics-Based Drug Discovery, Personalized Medicine, Bioinformatics, Drug Repurposing, Gene-Drug Interactions, Clinical Data Integration, Biomarker Identification,*

[1] College of Business, Westcliff University, Irvine, CA 92614, USA, Email: m.manik.407@westcliff.edu, (Corresponding Author), ORCID ID: https://orcid.org/0009-0005-6098-5213.
[2] Zicklin School of Business, Baruch College, The City University of New York, Email: sraboniclara.m@gmail.com, ORCID ID: https://orcid.org/0009-0002-4868-5371.
[3] Harrison College of Business and Computing, Southeast Missouri State University, Cape Girardeau, Missouri 63701, USA, Email: fkarim2s@semo.edu, ORCID ID: https://orcid.org/0009-0001-4480-9907.
[4] School of Business, International American University, Los Angeles, CA 90010, USA, Email: mdalamgirmiahiau@gmail.com, ORCHID ID: https://orcid.org/0009-0005-5780-125X.
[5] Department of Computer Science, Maharishi International University, Fairfield, Iowa 52557, USA, Email: shafiqswh@gmail.com, ORCID ID: https://orcid.org/0009-0008-9067-4987.
[6] School of Business, International American University, Los Angeles, CA 90010, USA, Email: mdasikurrahmanchy21@gmail.com, ORCID ID: https://orcid.org/0009-0002-6550-7104.
[7] College of Graduate and Professional Studies, Trine University, Detroit, Michigan, USA, Email address: muhammadadnan441@outlook.com, ORCID ID: https://orcid.org/0009-0001-6175-3618
[8] Department of Information Technology,Washington University of Science and Technology, Alexandria VA 22314, USA, Email: abus.student@wust.edu, ORCID ID: https://orcid.org/0009-0006-3147-1755

Introduction

Overview of Precision Medicine and its Significance in Modern Healthcare.

Medical treatments from precision medicine use individual-specific information about genes, besides environmental factors, along with life choices for personal healthcare planning. Specific healthcare strategies that match individual patients use identified group specifications to produce optimized treatment results(Segun, 2024). Precision medicine development was driven when genomic sequencing teamed up with big data analytics and artificial intelligence technologies allowed medical providers to better examine big databases and find the most effective treatments (Kalusivalingam et al., 2021).The main advantage of precision medicine is that it produces superior preventive care outcomes and improved therapeutic practices. The scientific development of oncological precision medicine has allowed researchers to build treatments targeting specific tumor genetics, which resulted in better therapy results and reduced undesirable outcomes (Kolawole, 2024). Health professionals use genetic profiling to eliminate treatment inefficiencies, which enables them to choose the best treatments early while lowering healthcare costs. Better predictive models emerged from the combination of big data analytics and AI advancements, which transformed precision medicine. Technological progress created tools for enhanced treatments to improve disease management in cancer patients together with the handling of cardiovascular challenges and unusual genetic conditions (Elguoshy and Hashem, 2024).Precision medicine enables healthcare to evolve through individualized medicine which takes into consideration a combination of heredity and environmental elements and life habits. The medical field strongly depends on this development because it provides disease prevention capabilities and treats diseases with enhanced effectivity while cutting overall healthcare expenses (Zalli et al., 2023).



Figure No.01: Global Precision Medicine Market Growth From 2024-2032

Global Precision Medicine Market Growth The precision medicine market around the world expanded at a quick rate since the development of genomics and artificial intelligence along with big data analytics. The 2017 market value reached $49 billion but researchers expect the market to surpass $140 billion by 2026. The market demonstrates strong growth because organizations invest more in biopharmaceutical research while AI reinforces drug discovery practices, and patients need individualized treatment approaches. Market expansion primarily results from high chronic disease rates, which include cancer together with cardiovascular diseases and rare

genetic conditions. The application of precision medicine enables doctors to deliver treatment specifically designed for individual patients, which leads to superior treatment results as well as fewer adverse effects. The market experiences increased expansion because governments, together with private sectors, dedicate substantial funds toward biomedical innovations and genomics research. AI-Driven Drug Discovery Models Modern drug research benefits from AI technology, which analyzes vast data collections and predicts drug reactions as well as detects precise therapeutic targets, making discoveries more successful.

Challenges in Traditional Drug Discovery

High Costs

Traditional drug development operates as an exceptionally costly pathway since pharmaceutical companies must invest billions of dollars before they release a medicinal product to the market. The total cost to develop new pharmaceutical products amounts to an estimated $2.6 billion because researchers need to conduct basic research along with preclinical studies and multiple clinical evaluation (Singh et al., 2022). The substantial expenditure of drug development stems mainly from unsuccessful clinical candidates because most tested substances cannot survive the complete drug development pipeline. The expensive nature of developing new medications restricts innovation, mainly when targeting rare diseases, because there exists inadequate market demand to warrant the development costs (Parasuraman, 2018).

Long Timelines

The entire drug discovery pathway extending from research through regulatory approval lasts 10 to 15 years, which is an extremely long period. Multiple regulatory examinations along with preclinical testing and multiple clinical trial phases slow down extensive drug testing due to safety and medicinal effectiveness confirmation requirements (Blanco-Gonzalez et al., 2023).

Lack of Personalization

Drug discovery through traditional methods provides mass-produced medications for multiple patients who do not consider individual health needs (Hon & Lee, 2017). The failure of conventional treatments develops because their lack of understanding about gene-based patient responses leads to dangerous medical side effects and insufficient therapeutic results for selected patient demographics. Medical practice without personalization produces insufficient drug discovery methods which prompt doctors to adjust dosages by trial and error. They should adopt exact data-based methods.



Figure No.02: Regression Analysis, AI investment Vs Drug Approval Rate

Role of AI & Machine Learning:

Enhancing Efficiency in Drug Discovery

Drug discovery receives its current form from artificial intelligence and machine learning systems through their ability to accelerate drug development procedures. Medicines are discovered faster through AI-generated processing of extensive biological data, which identifies chemical dependencies to locate potential pharmaceuticals (Winkler, 2020).AI examine extensive compounds for their optimal drug candidates, which reduces drug development duration from years to months (Rathore et al., 2021). AlphaFold from DeepMind created a breakthrough in protein structure prediction that changed protein folding study approaches because its capabilities benefit drug development (Mhlanga, 2022). The amalgamation of AI approaches accomplishes laboratory automation as well as chemical synthesis optimization and enhanced data analysis reducing laboratory duration and leading to better discovery outputs (Akkara and Kuriakose, 2019).

Drastic Shortening Occurs During Drug Discovery and Development Processes

AI algorithms quickly evaluate pharmaceutical databases for drug reassignment purposes through their assessment capabilities speeding up clinical trial procedures (Schneider, 2018). Machine learning models identify successful drug compounds enabling researchers to avoid unusable trial processes due to their drug-target interaction prediction abilities (Sneader, 2005).The pharmaceutical firms Atomwise and Insilico Medicine use artificial intelligence to discover new drug compounds that traditionally required extensive development periods (Jas and Kirschning, 2003).The selection of appropriate patient groups by AI enhances clinical trial prospects and reduces trial failures, which leads to improved drug approval chances (Paul et al., 2010).

Enabling Patient-Specific Treatments

AI and ML technologies that generate customized treatment plans from biological members and environmental components along with patient life expressions. AI genomic database analysis, medical personnel discover disease biomarkers alongside pharmaceutical responses to generate

customized healthcare plans for individual patients (Scheetz et al., 2019).IBM Watson applies artificial intelligence to evaluate cancer patients' biological signatures so it identify individualized medical treatments based on their unique genetic makeup (Ho et al., 2020).Machine learning models under AI control make predictions about patient adverse drug reactions, which reduces side effects and provides safer treatment choices to patients (Lorenzo, et al., 2024). Patient-specific, mechanistic models of tumor growth incorporating artificial intelligence and big data.

Big Data Analytics in Genomics:

The importance of analyzing large genomic datasets for drug discovery.



Figure No.03: Application for Drug Designing and Discovery & Stage and Description

The Role of Big Data in Genomic Research

The human genome has 3 billion base pairs, which makes genomic assessment an operation that requires tremendous data processing capacity. The analytical power of big data enables researchers to process large datasets effectively, which leads to genetic mutation-disease relationship identification (He et al., 2017). Through machine learning algorithms together with artificial intelligence bioinformatics tools, researchers extract previously hidden connections from massive genomic databases, which traditional methods cannot process because of their

large data volume and complex structure. Memorized genetic variations associated with illnesses recognized through Genome-Wide Association Studies that employ big data evaluation across multiple thousand genomic records (Frizzo-Barker et al., 2016). Genetic variant recognition precision as well as gene expression analysis and drug response prediction capabilities come from IBM Watson and Google Deep Variant's AI bioinformatics solutions (Madhavram et al., 2023). Modern sequencing technologies, particularly Next-Generation Sequencing cause vast genomic data production. Big data analysis allows researchers to investigate such datasets to chart genetic variations while spotting disease risks and making improved pharmaceutical treatments (Ioannidis and Khoury, 2018).

Genomic Big Data and Drug Discovery

AI-powered genomic data examination enables scientists to locate disease-individual mutations that researchers convert into drug targets (Taglangm and Jackson, 2016). The integration of patient genomic information with clinical history data using big analytics drives physicians to create individualized therapy plans that lower the occurrence of drug-related side effects as well as enhance medical results. The analysis of patient genetics produces significant benefits for selecting appropriate drugs to treat cancer patients (Chen and Butte, 2016).AI calculates drug toxicity and effectiveness through genomic assessments together with drug response data prior to clinical trials. The utilization of this method decreases the frequency of drug development failures and improves medical safety for patients (Kim and Hoshida, 2016).

Challenges and Future Prospects

The advantages of genomic big-data analysis face three main obstacles: storage management, privacy issues and computational expenses. Genomic data sharing needs proper ethical oversight before patient information remains confidential (Frizzo-Barker et al., 2016).The combination of quantum computing with federated learning together with blockchain-based protection of data brings future transformations to genomic big data analytics. These technological advances speed up data handling operations and maintain data security standards while improving scientific research cooperation between institutions (Dopazo, 2014). The revolution in drug discovery through genomics occurs due to big data analysis, which allows quick processing of enormous genomic information collections. Modern pharmacology benefited significantly from big data analytics because it enables the detection of genetic targets while advancing personalized treatment approaches with forecasting drug effectiveness. The future of precision medicine advances worldwide through precision medicine improvements driven by AI and big data genomic integration as computational techniques evolve (Low et al., 2018).

Research Objectives:

Modern drug discovery processes in genomics become more efficient through Artificial Intelligence combined with Machine Learning and Big Data Analytics. The main purpose behind this study is to identify the ways in which innovative technologies boost efficiency alongside improving precision and personalization of drug development procedures. The processing features of AI models facilitate large genomic dataset analysis to detect disease markers while expediting the discovery of new drugs. Research leveraging deep learning and natural language processing deployment methods allows scientists to analyze intricate genetic patterns and then predict disease susceptibilities with high-level accuracy. The process of drug-target interaction forecasting depends on machine learning alongside the optimization of drug creation and drug repurposing candidate selection. The analysis of historical data by ML algorithms enables the

system to detect patterns that relate to drug efficacy together with toxicity and molecular interactions.

Literature Review

Evolution of Precision Medicine

The development of precision medicine occurred through genomic research combined with artificial intelligence gadgets along with extensive big data analysis methods from past years. Such change established current medical practice because providers moved away from following standard protocols toward designing treatments for individual patients (Abrahams and Downing, 2024). Patients undergo treatment under precision medicine by combining genomic testing with lifestyle and environmental evaluations to reach better treatment results with minimized adverse reactions (Papadopoulou et al., 2023). Today's research fields largely depend on genomic sequencing for the reason that this technique reveals how genetic differences modify disease propensity and drug response (Curigliano, 2018).Scientists recognized the Human Genome Project as a major breakthrough for precision medicine when it finished its objective in 2003. The accomplishment delivered scientists a complete genetic blueprint that let them progress studies of genetic testing methods as well as biomarkers and targeted therapeutic development (Ginsburg and Phillips, 2018). The completion of the Human Genome Project, NGS sequencing technologies became available for quick and affordable whole genome sequencing. The most recent technological breakthroughs allow scientists to detect disease-linked genetic mutations that involve cancer disruptions along with brain disorders and heart problems (Canonica et al., 2023). Forecasting disease responses becomes possible when these devices help maximize pharmaceutical research along with patient-specific therapy development (Dugger et al., 2018).

AI and Machine Learning in Drug Discovery

Drug science advanced remarkably because artificial intelligence systems made precision and affordability better along with improved efficiency. Drug development processes through conventional methods demand twelve years to generate a single new drug at a high expense (Yang and Baumgartner, 2022). CNNs process molecular data efficiently and detect possible drug candidates because of their effective design, while RNNs use genetic sequences to predict drug toxicity measurement and helpfulness levels (Thatoi et al., 2024). Random Forest and Support Vector Machines for executing drug-target interaction predictions. The application of Bayesian models extends across pharmaceutical work to improve drug formulation optimization and fulfill preclinical side effect evaluation purposes. Drug discovery significantly benefits from Natural Language Processing because it helps extract beneficial data insights from enormous medical literature and trial documentation. The AI platforms known as IBM Watson, together with Google's DeepMind, analyze large quantities of scientific literature to discover covert patterns between diseases and drug effects (Farid et al., 2023). Learning serves as a crucial component in drug discovery pipelines because it helps optimize chemical synthesis pathways together with enhancing drug candidate selection (Berens et al., 2023). The advancement of AI and ML models in drug discovery operates against obstacles including insufficient data quality and uninterpretable models and regulatory administrative barriers. The evolution of AI technologies enables precise medical treatments because experts predict it speed up the discovery of effective drugs for different diseases (Sarkar et al., 2024).

Big Data and Bioinformatics:

Bioinformatics and big data maintain their position as important genomic research tools that evaluate big data collections produced by DNA sequencing and gene expression research and protein interaction studies (Greene et al., 2014). Daily genomic data production brought on by high-throughput sequencing technology prompts the development of advanced computational tools and analytical frameworks to extract important insights (Li et al., 2019). Big data analytics serves as a vital tool for disease association learning among genetic variations and enables the prediction of drug responses together with the discovery of fresh therapeutic targets. The drug discovery processes become faster while ML alongside AI methods improves the efficiency of genomic research by extracting patterns from extensive datasets (da Silva et al., 2019). The primary bioinformatics application of big data involves genome-wide association studies because these examinations perceive genetic differences within populations to establish disease-genetic gene relationships. GWAS research using this method has established vital knowledge about disease genetics for cancer and diabetes along with cardiovascular conditions (Greene et al., 2016). The integration of big data with bioinformatics affects research and medicine through obstacles comprised of privacy issues and ethical matters together with standardizing data sharing protocols. Data integrity and patient confidentiality achieved by implementing strong regulatory frameworks with advanced cybersecurity mechanisms to deal with these challenges (Nagaraj and Sridhar, 2018).

Recent Case Studies and Applications:

The pharmaceutical industry experienced a breakthrough through AI-driven drug discovery because this innovation cut the development timeline and expenses needed for new drug development (Demirbaga, et al., 2024). Research studies show how AI-based operation systems help discover new medication treatments successfully. Insilico Medicine demonstrated the power of AI through their design of an IPF drug candidate in 46 days at their biotechnology company. The company utilized GANs in 2020 to find a fresh drug candidate within 46 days, which normally requires multiple years to achieve through traditional methods. The generated compound through AI technology completed preclinical tests, following which it confirmed its utility in fighting IPF-related proteins (Liu and Han, 2023). Pharmaceutical researchers receive essential information for developing targeted therapies because AlphaFold an AI model accurately predicts protein 3D structures (Shah, 2012).Artificial intelligence technology proves effective for conducting drug discovery research within cancer fields. AI made it possible to rapidly find new uses for drugs, which led to the FDA's emergency authorization of the drug treatment for COVID-19 patients (Shah, 2012). AI-driven pharmaceutical company discovered small-molecule drugs for neurodegenerative disorders with the help of deep learning techniques. AtomNet served as their AI model to predict the binding affinity between millions of compounds

and disease targets and facilitated the discovery of novel medication candidates suitable for treating Parkinson and multiple sclerosis (Altman, 2016).

Company/Research	Drug Discovered/Repurposed	Disease Targeted	AI Approach Used	Key Outcome
Insilico Medicine	Novel DDR1 kinase inhibitor	Idiopathic Pulmonary Fibrosis (IPF)	Generative Adversarial Networks (GANs)	Discovered in 46 days, passed preclinical trials
DeepMind (AlphaFold)	Protein structure predictions	Various diseases (e.g., Alzheimer's, Parkinson's)	Deep Learning-based Structural Prediction	Solved protein folding problem, aiding drug discovery
Benevolent AI	Baricitinib (repurposed)	COVID-19	AI-based Drug Repurposing	FDA emergency use authorization
Atomwise (AtomNet)	Small-molecule drugs	Neurodegenerative diseases (e.g., Multiple Sclerosis, Parkinson's)	Deep Learning for Molecular Docking	Identified promising candidates for neurodegenerative disorders
MIT & Harvard Researchers	Halicin (antibiotic)	Multi-drug-resistant bacterial infections	AI-based Antibiotic Discovery	Discovered new antibiotic effective against resistant strains

Table No.02: Recent AI-Driven Drug Discovery Case Studies

Methodology

Data Collection

The evolution of advanced medicine and pharmaceutical innovation needs extensive biomedical and genomic information acquisition conducted by AI systems. Sources of research mainly include public databases paired with electronic health records and high-throughput sequencing technologies and biobanks provide vital additional elements. Technical data collected by scientists allows them to analyze genetic patterns as well as predict disease risk and develop disease-specific clinical options. Big data analytics performs fast processing on substantial genomic information, which speeds up drug research programs and creates better individual healthcare solutions.

Machine Learning Models:

Drug discovery programs that use genomic science require machine learning models to find better methods of disease classification and biomarker discovery in addition to drug candidate evaluation techniques. Drug targets identified through genomic information analysis when artificial intelligence learning tools work with temperature control alongside neural networks and convolutional models. The speed of drug development increases with reinforcement learning since this method allows chemists to simulate productive compound reactions during chemical simulations.

Big Data Analytics Framework:

Through its efficient data handling capabilities, the Big Data Analytics Framework improves the process of finding new drugs through genomic studies. This framework contains two baseline steps, starting with data preprocessing integration alongside raw genomic information cleaning, which leads to extraction and information normalization to achieve internal and external source uniformity. The key purpose of high-performance computing systems integrated with cloud solutions deals with large amounts of genomic data because these solutions offer required computational strength and built-in storage capabilities.

Computational Biology & Bioinformatics Tools

Artificial intelligence models using drug interaction simulations deliver their primary function through which machine learning systems predict drug substances' biological target responses. The utilization of simulated models reduces the demand for laboratory testing, which enables developers to achieve better drug discovery results using their time saved and funds. AI applications analyzing genomic data enable researchers to detect which diseases affect individual bodies simultaneously with how these bodies react to medicines and what treatment solutions would deliver optimal results for personalized medicine.

Ethical Considerations & Challenges:

A comprehensive research project should study technical limitations and ethical matters related to AI-based precision medicine and genomics-based drug discovery for establishing fair implementation procedures. Genomic data privacy suffers mainly from security requirements to secure them against unauthorized access and breaches. Healthcare provider-patient trust development requires the implementation of GDPR and HIPAA regulations because they secure patient information. The proper diversity of major population groups remains absent in AI model datasets because these patterns demonstrate biased characteristics. The inaccurate treatment results occur because of biased predictions affecting the population segments that belong to these demographic groups.

Results and Discussion

Effectiveness of AI in Drug Discovery:

Pharmaceutical research during modern times heavily depends on drug discovery effectiveness, which AI-enabled models are capable of achieving. The combination of deep learning, reinforcement learning, and supervised learning methods allows large biological and chemical dataset analysis to determine drug effectiveness. The models deliver superior drug candidate identification results than traditional discovery methods, shorten development periods, and cut associated spending. Deep learning networks demonstrate peak performance in recognizing

compound patterns alongside binding connections through their performative evaluation techniques that combine CNNs and RNNs. The predictive models achieve superior performance compared to standard statistical strategies for drug efficacy prediction accuracy.

ML Model	Key Features	Advantages	Limitations	Use Cases
Supervised Learning	Uses labeled datasets for training	High accuracy with sufficient data	Requires large, labeled datasets	Disease classification, biomarker identification
Deep Learning (CNN, RNN)	Recognizes complex molecular patterns	Excels in feature extraction & pattern recognition	Computationally expensive	Drug-target interaction, molecular property prediction
Reinforcement Learning	Learning optimal drug candidate selection strategies	Self-improving with trial-and-error learning	Requires significant computational resources	Drug design, clinical trial simulations
Unsupervised Learning	Clusters and discovers patterns in unlabeled data	Identifies hidden drug-disease relationships	Lower accuracy compared to supervised models	Novel drug discovery, patient stratification
Hybrid Models	Combination of ML techniques	Improved prediction by integrating strengths	Increased complexity and computation costs	Personalized medicine, multi-omics data integration

Table No.03: The Performance of Different Machine Learning Models in Predicting Drug Efficacy:



Figure No.04: ML Models -Prediction Accuracy and Trend of ML Model Performance

Impact on Personalized Medicine:

Through the application of AI along with machine learning technology, personalized medicine achieves better treatment effectiveness by creating specific treatment approaches based on individual genetic composition. Williams College researchers prove that genomic information

evaluated by AI systems successfully detects diseases early and identifies optimal medications in addition to minimizing negative treatment side effects. AI-assisted precision medicine in oncology allows better cancer treatments because it predicts how patients respond to targeted therapies. The application of AI in genomic analysis has enabled the creation of personalized treatments for uncommon genetic conditions that deliver better survivorship and well-being outcomes for patients. Technological progress demonstrates how artificial intelligence revolutionizes medical care through precise patient treatment.



Figure No.05: ML Model Usage in Drug Discovery & Efficiency Usage of ML Models

Comparison with Traditional Methods:

Biotechnology drugs created through AI algorithms show superior performance than traditional methods regarding time efficiency, lower costs, and better prediction capabilities. The conventional drug development process lasts a decade or longer while requiring billions of dollars because it depends heavily on trial-and-error testing and extensive laboratory research. Drug candidates become easier to find through AI and machine learning models that review vast genomic and biomedical information to generate accurate and swift predictions. AI systems decrease clinical trial failures through early assessments that determine drug effectiveness and possible adverse results. Pharmaceutical companies use artificial intelligence technology to boost research innovations at reduced expenses while generating better results for patients.

Company	Headquarters	Key Focus Areas	Notable Achievements
DeepMind (Alphabet)	UK	AI for protein folding (AlphaFold)	Developed **AlphaFold**, revolutionizing protein structure prediction
Insilico Medicine	Hong Kong	AI-driven drug discovery and biomarker identification	Identified novel drug candidates using generative AI
Benevolent AI	UK	AI for drug target identification and development	Discovered potential COVID-19 treatment using AI
Exscientia	UK	AI for automated drug design	Designed the world's first AI-created drug in human trials
Recursion	USA	AI and	Utilizes computer vision and

Pharmaceuticals		bioinformatics for drug discovery	AI to repurpose existing drugs
Schrödinger	USA	AI and computational physics for molecular modeling	Uses AI-driven simulations to optimize drug candidates
Atomwise	USA	AI for small molecule drug discovery	Uses deep learning for virtual screening of compounds
Path AI	USA	AI for pathology and precision medicine	AI-powered diagnostics for disease identification

Table No.03: The Most Important Companies in the World Specializing in AI-Driven Drug Discovery and Precision Medicine:

Challenges and Limitations:

Various hurdles along with limitations block AI-driven drug discovery from reaching its total implementation potential. Secure protection for genomic data along with patient health information has become a primary challenge because of privacy and data safety issues. Achieving compliance with GDPR together with HIPAA represents an essential task that remains difficult to navigate. Implementing AI models faces difficulties in terms of their interpretability level. Researchers struggle to understand drug prediction processes from machine learning and deep learning models, specifically neural networks, because these algorithms function as black boxes. The absence of transparency creates problems regarding trust along with reliability and regulatory requirements for the clinical environment.

Company	**Headquarters**	**Key Focus**	**Notable Achievements**	**AI Technologies Used**
DeepMind (Google Health)	United Kingdom	AI-driven drug design and protein folding	Developed AlphaFold for protein structure	Deep Learning, Neural Networks

			prediction	
Benevolent AI	United Kingdom	AI-powered drug discovery for diseases	Identified potential drug candidates for ALS and COVID-19	Machine Learning, Knowledge Graphs
Insilico Medicine	Hong Kong	AI-driven small molecule drug discovery	Discovered AI-designed drug for fibrosis in record time	Generative Adversarial Networks (GANs), Deep Learning
Atomwise	United States	AI-based molecular screening and drug discovery	AI-powered screening for COVID-19 treatments	Convolutional Neural Networks (CNNs), Deep Learning
Recursion Pharmaceuticals	United States	AI-driven high-throughput drug discovery	Integrated AI and bioinformatics for rare disease treatment	Computer Vision, Automated Experimentation
Schrödinger	United States	Computational chemistry and AI-assisted drug design	Developed AI models for molecular simulations	Quantum Mechanics, Machine Learning
Exscientia	United Kingdom	AI-led precision medicine and drug optimization	Discovered the first AI-designed drug to enter human trials	Reinforcement Learning, Active Learning
Cyclica	Canada	AI-driven polypharmacology for drug discovery	Predicts of drug interactions and side effects using AI	Graph Neural Networks, Machine Learning
BioXcel Therapeutics	United States	AI in neuropsychiatric and immuno-oncology drugs	AI-identified drug candidates for mental health disorders	Natural Language Processing (NLP), Deep Learning
IBM Watson Health	United States	AI for drug repurposing and personalized medicine	AI-assisted research on oncology and chronic diseases	Deep Learning, NLP, Big Data Analytics

Table No.06: Leading Global Companies in AI-Driven Drug Discovery

Future Directions

Integration of Quantum Computing with AI

Quantum computing systems integrated with artificial intelligence capabilities drive revolutionary changes in research about drugs and genomics. Quantum computing possesses capabilities to perform exponential computation speed-ups of complex processes beyond classical computational speed boundaries. AI models performing deep learning and molecular simulations need very large processing capabilities to evaluate substantial genomic information while determining how drugs react with each other.

Advancements in Explainable AI

High-quality medical and clinical practices depend on transparent AI models because AI continues developing drug discovery and precision medicine technologies. XAI researchers as well as healthcare professionals and regulatory bodies succeed in making sense of the complicated data networks produced by ML models. Particularly deep learning and neural networks operate as hidden boxes because their predictive operations remain inaccessible to human understanding.

AI-Driven Drug Repurposing

XAI creates possibilities for researchers as well as healthcare professionals and regulatory bodies to grasp complicated information networks from ML model outputs. Traditional neural networks, together with deep learning AI models, operate within black box functions retaining their operational secrecy despite their insufficient prediction method explanations. XAI enables scientists to identify crucial genetic markers and explain how predicted effective compounds work so they confirm the accuracy of AI-generated outcomes in drug discovery processes.



Regulatory & Ethical Frameworks

The implementation of complete ethical frameworks with strict regulatory protocols by laboratory researchers conducting medical studies using AI for drug discovery and genomics work ensures security standards, meets governing standards and demonstrates openness. Two primary concentrations make up medical frameworks by protecting patient information while creating standards for verifying medical solutions that originate from AI systems that must adhere to distinct clinical parameters. Data privacy laws such as the General Data Protection Regulation in Europe and the Health Insurance Portability and Accountability Act in the U.S. set strict guidelines for handling patient data securely. Policies regarding responsible AI require

joint action between governmental organizations and AI developers who research and advance AI technologies.

Conclusion

Summary of Findings

The drug discovery advancement depends on artificial intelligence-supported machine learning algorithms to explore new drug components for developing patient prediction models alongside treatment methods. Services based on genomic big data analysis allow science researchers to examine extensive genetic information for marker discovery purposes that lead to personalized therapeutic strategies. The development of AI-driven discovery tools in pharmaceutical research decreases costs while speeding up the performance of drug development more efficiently than traditional methods. Deep learning systems coupled with reinforcement learning produce high-quality results in medical diagnosis and biomarker discovery together with drug assessment. Genomic research at scale receives improvement power from the combination of high-performance computing infrastructure with cloud-based solutions. Multiple advantages emerged from AI system development, although present obstacles include privacy issues and discriminatory algorithms and regulatory standards.

Implications for Healthcare

AI systems with big data technologies in precision medicine create substantial changes across all healthcare facilities. The main value stems from using treatments that align with unique patient features consisting of genetic information and behavioral expressions and their medical history. Such medical therapy generates enhanced drug effectiveness alongside reduced adverse drug reactions for patients, yielding optimal clinical treatment results. The implementation of AI for precision medicine reduces healthcare prices because AI optimizes pharmaceutical research procedures and has the advantage of correctly recommending medication avoidance. Developers need more than a ten-year period and substantial costs to introduce drugs commercially because pharmaceutical development takes a prolonged time frame when released to markets.

Call for Further Research

The potential transformation of medical care through artificial intelligence creates various research challenges for its deployment in precision medicine. AI models face their biggest challenge because of their inability to explain their operating processes. The operational black-box nature of several machine learning and deep learning algorithms creates difficulties for researchers and clinicians to identify specific prediction processes. Medical decision systems need improved capabilities in explainable AI techniques to build trust and transparency because this ensures proper accountability in decision-making processes. New AI healthcare solutions outpace worldwide regulatory organizations in their capability to match modern technological changes. Healthcare institutions need to establish standardized procedures that address privacy matters and set guidelines for ethical AI deployment systems and patient protection rules right away. Full adherence to healthcare regulations at domestic and worldwide levels enables smooth AI implementation while reducing organizational exposure to risks generated from model aberrations and unsafe handling of data.

References

Abrahams, E., & Downing, G. J. (2024). On the modern evolution of personalized medicine. In The New Era of Precision Medicine (pp. 1-25). Academic Press.

Akkara, J. D., & Kuriakose, A. (2019). Role of artificial intelligence and machine learning in ophthalmology. Kerala Journal of Ophthalmology, 31(2), 150-160.

Altman, R. (2016). Current Progress in bioinformatics 2016. Briefings in bioinformatics, 17(1), 1-1.

Austin CP. Translating translation. Nat Rev Drug Discov. 2018 Jul;17 (7):455–456. doi: 10.1038/nrd.2018.27

Beneke F, Mackenrodt M-O. Artificial intelligence and collusion. IIC. 2019;50(1):109–134. doi: 10.1007/s40319-018-00773-x

Berens, P., Cranmer, K., Lawrence, N. D., von Luxburg, U., & Montgomery, J. (2023). AI for Science: an emerging agenda. arXiv preprint arXiv:2303.04217.

Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A., & Garcia-Fandino, R. (2023). The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals, 16(6), 891.

Canonica, G. W., Varricchi, G., Paoletti, G., Heffler, E., & Virchow, J. C. (2023). Advancing precision medicine in asthma: evolution of treatment outcomes. Journal of Allergy and Clinical Immunology, 152(4), 835-840.

Chen, B., & Butte, A. (2016). Leveraging big data to transform target selection and drug discovery. Clinical Pharmacology & Therapeutics, 99(3), 285-297.

Choi SW, Mak T-H, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759–2772. doi: 10.1038/s41596-020-0353-1

Curigliano, G. (2018). Cancer Evolution as the New Frontier of Precision Medicine. Mechanisms of Drug Resistance in Cancer Therapy, 289-297.

da Silva, D. S. M., da Silva, W. M., RuiZhe, G., Bernardi, A. P., Mariano, A. M., & Holanda, M. (2019, November). Big data trends in bioinformatics. In 2019 IEEE international conference on bioinformatics and biomedicine (BIBM) (pp. 1862-1867). IEEE.

Demirbaga, Ü., Aujla, G. S., Jindal, A., & Kalyon, O. (2024). Big Data Analytics in Bioinformatics. In Big Data Analytics: Theory, Techniques, Platforms, and Applications (pp. 265-284). Cham: Springer Nature Switzerland.

Dopazo, J. (2014). Genomics and transcriptomics in drug discovery. Drug discovery today, 19(2), 126-132.

Dudbridge F, Wray NR. Power and predictive accuracy of polygenic risk scores. PloS Genet. 2013;9(3):e1003348. doi: 10.1371/journal. pgen.1003348

Dugger, S. A., Platt, A., & Goldstein, D. B. (2018). Drug development in the era of precision medicine. Nature reviews Drug discovery, 17(3), 183-196.

Elguoshy, A., & Hashem, A. M. (2024). Introduction to genomic-based clinical applications. In Microbial Genomics: Clinical, Pharmaceutical, and Industrial Applications (pp. 97-115). Academic Press.

Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019 Jan;25(1):24–29. doi: 10.1038/s41591- 018-0316-z

Fang X, Liu Y, Ren Z, et al. Lilikoi V2. 0: a deep learning–enabled, personalized pathway-based R package for diagnosis and prognosis predictions using metabolomics data. Gigascience. 2021;10(1):giaa162. doi: 10.1093/gigascience/giaa16

Farid, F., Bello, A., Ahamed, F., & Hossain, F. (2023). The roles of ai technologies in reducing hospital readmission for chronic diseases: a comprehensive analysis. Preprints. org). doi, 10, 1-19.

Feldman AB. Clinical and translational research; personalized Medicine; precision medicine—what's in a name? Clin Transl Sci. 2015;8(3):171–173. doi: 10.1111/cts.12302

Frizzo-Barker, J., Chow-White, P. A., Charters, A., & Ha, D. (2016). Genomic big data and privacy: challenges and opportunities for precision medicine. Computer Supported Cooperative Work (CSCW), 25, 115-136.

Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: from science to value. Health affairs, 37(5), 694-701.

Greene, A. C., Giffin, K. A., Greene, C. S., & Moore, J. H. (2016). Adapting bioinformatics curricula for big data. Briefings in Bioinformatics, 17(1), 43-50.

Guyon I, Elisseeff A. An introduction to variable and feature selection. J Mach Learn Res. 2003;3(Mar):1157–1182.

Han R, Yoon H, Kim G, et al. Revolutionizing medicinal chemistry: the application of artificial intelligence (AI) in early drug discovery. Pharmaceuticals (Basel). 2023;16(9):1259. doi: 10.3390/ph16091259

Hartl D, de Luca V, Kostikova A, et al. Translational precision medicine: an industry perspective. J Transl Med. [2021 Jun 5];19 (1):245. doi: 10.1186/s12967-021-02910-6

He, K. Y., Ge, D., & He, M. M. (2017). Big data analytics for genomic medicine. International journal of molecular sciences, 18(2), 412.

Ho, D., Quake, S. R., McCabe, E. R., Chng, W. J., Chow, E. K., Ding, X., ... & Zarrinpar, A. (2020). Enabling technologies for personalized and precision medicine. Trends in biotechnology, 38(5), 497-518.

Hon, K. L., & Lee, V. W. (2017). Challenges for drug discovery and development in China. Expert Opinion on Drug Discovery, 12(1), 105-113.

Ioannidis, J. P., & Khoury, M. J. (2018). Evidence-based medicine and big genomic data. Human molecular genetics, 27(R1), R2-R7.

Jas, G., & Kirschning, A. (2003). Continuous flow techniques in organic synthesis. Chemistry–A European Journal, 9(23), 5708-5723.

Kalinin, A. A., Higgins, G. A., Reamaroon, N., Soroushmehr, S., Allyn-Feuer, A., Dinov, I. D., ... & Athey, B. D. (2018). Deep learning in pharmacogenomics: from gene regulation to patient stratification. Pharmacogenomics, 19(7), 629-650.

Kalusivalingam, A. K., Sharma, A., Patel, N., & Singh, V. (2021). Leveraging Deep Learning and Random Forest Algorithms for AI-Driven Genomics in Personalized Medicine. International Journal of AI and ML, 2(3).

Kim, R. S., Goossens, N., & Hoshida, Y. (2016). Use of big data in drug development for precision medicine. Expert review of precision medicine and drug development, 1(3), 245-253.

Kolawole, O. O. (2024). AI-Driven Personalized Medicine and Drug Discovery.

Li, Y., Huang, C., Ding, L., Li, Z., Pan, Y., & Gao, X. (2019). Deep learning in bioinformatics: Introduction, application, and perspective in the big data era. Methods, 166, 4-21.

Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. Nat Rev Genet. 2015;16(6):321–332. doi: 10.1038/nrg3920

Liu, Y., Chen, Y., & Han, L. (2023). Bioinformatics: Advancing biomedical discovery and innovation in the era of big data and artificial intelligence. Innov. Med, 1(1), 100012-1.

Lorenzo, G., Ahmed, S. R., Hormuth II, D. A., Vaughn, B., Kalpathy-Cramer, J., Solorio, L., ... & Gomez, H. (2024). Patient-specific, mechanistic models of tumor growth incorporating artificial intelligence and big data. Annual Review of Biomedical Engineering, 26.

Low, S. K., Zembutsu, H., & Nakamura, Y. (2018). Breast cancer: The translation of big genomic data to cancer precision medicine. Cancer science, 109(3), 497-506.

Madhavram, C., Boddapati, V. N., Galla, E. P., Sunkara, J. R., & Patra, G. K. (2023). AI-Powered Insights: Leveraging Machine Learning and Big Data for Advanced Genomic Research In Healthcare. Available at SSRN 5029402.

Mhlanga, D. (2022). The role of artificial intelligence and machine learning amid the COVID-19 pandemic: What lessons are we learning on 4IR and the sustainable development goals. International Journal of

Environmental Research and Public Health, 19(3), 1879.
Nagaraj, K., Sharvani, G. S., & Sridhar, A. (2018). Emerging trend of big data analytics in bioinformatics: a literature review. International Journal of Bioinformatics Research and Applications, 14(1-2), 144-205.
Paananen J, Fortino V. An omics perspective on drug target discovery platforms. Brief Bioinform. 2020;21(6):1937–1953. doi: 10. 1093/bib/bbz122
Papadopoulou, E., Pepe, G., Konitsiotis, S., Chondrogiorgi, M., Grigoriadis, N., Kimiskidis, V. K., ... & Nasioulas, G. (2023). The evolution of comprehensive genetic analysis in neurology: implications for precision medicine. Journal of the Neurological Sciences, 447, 120609.
Parasuraman, S. (2018). Herbal drug discovery: challenges and perspectives. Current pharmacogenomics and personalized medicine, 16(1), 63-68.
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews Drug discovery, 9(3), 203-214.
Rathore, M. M., Shah, S. A., Shukla, D., Bentafat, E., & Bakiras, S. (2021). The role of ai, machine learning, and big data in digital twinning: A systematic literature review, challenges, and opportunities. IEEE Access, 9, 32030-32052.
Runcie DE, Crawford L, Epstein MP. Fast and flexible linear mixed models for genome-wide genetics. PloS Genet. 2019;15(2): e1007978. doi: 10.1371/journal.pgen.1007978
Sarkar, A., Singh, P., & Varkey, M. (2024). Healthcare Artificial Intelligence in India and ethical aspects. In AI, consciousness and the New Humanism: Fundamental reflections on minds and machines (pp. 107-150). Singapore: Springer Nature Singapore.
Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal variants by statistical fine-mapping. Nat Rev Genet. 2018;19(8):491–504. doi: 10.1038/s41576-018-0016-z
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019). Engineering patient-specific cancer immunotherapies. Nature biomedical engineering, 3(10), 768-782.
Schneider, G. (2018). Automating drug discovery. Nature reviews drug discovery, 17(2), 97-113.
Segun, A. F. (2024). Advances in personalized medical therapeutics: Leveraging genomics for targeted treatments. International Journal of Research Publication and Reviews, 5(10), 2921-2933.
Shaffie A, Soliman A, Fu X-A, et al. A novel technology to integrate imaging and clinical markers for non-invasive diagnosis of lung cancer. Sci Rep. 2021;11(1):4597. doi: 10.1038/s41598-021-83907-5
Shah, N. H. (2012). Translational bioinformatics embraces big data. Yearbook of medical informatics, 21(01), 130-134.
Singh, D. B., Pathak, R. K., & Rai, D. (2022). From traditional herbal medicine to rational drug discovery: strategies, challenges, and future perspectives. Revista Brasileira de Farmacognosia, 32(2), 147-159.
Sneader, W. (2005). Drug discovery: a history. John Wiley & Sons.
Speck-Planche A, Dias Soeiro Cordeiro MNl JACS. Speeding up early drug discovery in antiviral research: a fragment-based in silico approach for the design of virtual anti-hepatitis C leads. ACS Comb Sci. 2017;19(8):501–512. doi: 10.1021/acscombsci.7b00039
Speck-Planche A, Mndsjfmc C. Chemoinformatics for medicinal chemistry: in silico model to enable the discovery of potent and safer anti-cocci agents. Future Med Chem. 2014;6(18):2013–2028. doi: 10.4155/fmc.14.136
Taglang, G., & Jackson, D. B. (2016). Use of “big data” in drug discovery and clinical trials. Gynecologic Oncology, 141(1), 17-23.
Tsamardinos I, Greasidou E, GJMl B. Bootstrapping the out-of-sample predictions for efficient and accurate cross-validation. Mach Learn. 2018;107(12):1895–1922. doi: 10.1007/s10994-018-5714-4

van Grootel, R. J., Buchner, R., Wismeijer, D., & van der Glas, H. W. (2017). Towards an optimal therapy strategy for myogenous TMD, physiotherapy compared with occlusal splint therapy in an RCT with therapy-and-patient-specific treatment durations. BMC musculoskeletal disorders, 18, 1-17.

Winkler, D. A. (2020). Role of artificial intelligence and machine learning in nano safety. Small, 16(36), 2001883.

Yang, H., Feng, D., & Baumgartner, R. (2022). AI and Machine Learning in Drug Discovery. In Data Science, AI, and Machine Learning in Drug Development (pp. 63-93). Chapman and Hall/CRC.

Zalli, D., Mai, Z., Ferati, E., Ramaj, A., Bregu, R., & Pranjol, M. Z. I. (2023). Advancing Precision Medicine: Integrating Next-Generation Sequencing and Tumor Markers for Early Cancer Detection and Personalized Treatment. Handbook of Cancer and Immunology, 1-31.

Zeggini E, Gloyn AL, Barton AC, et al. Translational genomics and precision medicine: moving from the lab to the clinic. Science. 2019;365(6460):1409–1413. doi: 10.1126/science. aax4588.

Zhang Z, Ersoz E, Lai C-Q, et al. Mixed linear model approach adapted for genome-wide association studies. Nat Genet. 2010;42 (4):355–360. doi: 10.1038/ng.546

Zhou Q, Yong B, Lv Q, et al. Deep autoencoder for mass spectrometry feature learning and cancer detection. IEEE Access. 2020; 8:45156–45166. doi: 10.1109/ACCESS.2020.2977680